---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-079142"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2022-12-12T23:59:59+00:00"
generated_at: "2026-06-21T06:13:30.205703+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# INmune Bio extends shareholder rights plan to Dec 30, 2023 via Amendment No. 2

## Summary
- Board adopted Amendment No. 2 to Rights Agreement on December 9, 2022.
- Expiration date of the poison pill extended from Dec 30, 2022 to Dec 30, 2023.
- Amendment entered with VStock Transfer, LLC as rights agent.
- Prior amendment (Dec 2021) had extended the plan to Dec 30, 2022.

## SEC filing metadata
- accession: 0001213900-22-079142
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2022-12-12T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 1.01, 3.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390022079142/0001213900-22-079142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390022079142/ea169921-8k_inmunebio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-079142
- JSON: https://secwatch.observer/filing/0001213900-22-079142.json
- Plain text: https://secwatch.observer/filing/0001213900-22-079142.txt

## Key facts
- Material Agreements
  Inmune Bio, Inc. amended Amendment No. 2 to Rights Agreement with VStock Transfer, LLC (effective 2022-12-09).
  - Action: amendment
  - Counterparty: VStock Transfer, LLC
  - Effective: 2022-12-09
  source text: On December 9, 2022, the Company and VStock Transfer, LLC entered into Amendment No. 2 to Rights Agreement (“Amendment No. 2”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711754/000121390022079142/0001213900-22-079142-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.